Type 1 diabetes (T1D) is a chronic metabolic disorder characterized by autoimmune-mediated destruction of insulin-secreting beta cells in the pancreatic islets. 
| INTRODUC TI ON
Type 1 diabetes (T1D) is a chronic metabolic disorder characterized by autoimmune-mediated destruction of insulin-secreting beta cells in the pancreatic islets. 1 Estimated life expectancy for patients with T1D in a population-based sample indicated lower life expectancy compared with the general population without T1D. 2 Whole organ pancreas or pancreatic islet transplantation can potentially restore long-term normoglycemia, and select patients with T1D can potentially become insulin independent. Pancreas transplantation is currently accepted as a commonly carried out therapy. 3 To date, more than 35 000 pancreas transplants have been carried out worldwide 4 ; however, the procedure is associated with significant mortality and morbidity in the early transplant period. 5 A major benefit of islet transplantation is that it does not require major surgery. The treatment involves extracting sufficient numbers of pancreatic islets from the donor pancreas and infusing these through the portal vein into the patient's liver under local anesthesia. Excellent therapeutic effects of islet transplantation as a result of accurate blood glucose level-reactive insulin secretion, which cannot be reproduced by
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current drug therapy, have been confirmed. Currently, although all patients with T1D who underwent islet transplantation are not insulin independent, it is recognized as a safe and highly effective treatment for patients with impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHE). Meanwhile, some problems need to be solved, such as severe donor shortage for islet transplantation, necessity to search for alternative transplantation sites that can be more efficiently engrafted, and to develop alternative cell sources. In this review, we provide an outline on clinical islet transplantation (CIT). We also introduce the refinement that has been attempted to improve the clinical outcome, we then discuss future prospects based on the latest findings.
| B RIEF OVERVIE W OF CLINI C AL IS LE T TR AN S PL ANTATI ON
For patients with T1D, lifetime exogenous insulin administration is required to control blood glucose level. Some patients are at risk of IAH and SHE, 6 which have a negative impact on quality of life. In addition, blood glucose instability can cause various complications, such as retinopathy and neuropathy. pancreas-kidney (SPK) transplant. 4 Although pancreas transplantation is considered a proven therapy, some physicians are reluctant to recommend this procedure to patients because of its complexity and risks, particularly for pancreas transplant alone. 4 Islet transplantation is carried out to intraportally transfuse isolated pancreatic islets only, which constitute only 1%-2% of the pancreas. 9 This procedure was expected to be an ideal transplant therapy for patients with severe glycemic instability, and development aiming to improve this procedure has been undertaken worldwide. Ballinger and Lacy demonstrated a method for isolating pancreatic islets from rodents and confirmed in vivo function in 1972. 10 By the establishment of the islet isolation method called the Ricordi method, 11 the first case of clinical insulin independence was reported in 1990 by Scharp et al. 12 The number of clinical transplantations gradually increased; however, insulin independence after islet allotransplantation was difficult to achieve in the earliest years. The International Islet Transplant
Registry reported transplant outcomes of 237 patients with T1D
who received adult islet allografts between 1990 and 1999. The 1-year islet allograft survival (defined by basal C-peptide ≧0.5 ng/mL) rate was 41%, and 11% of the recipients were insulin independent at 1 year post-transplant. 13 The result seemed to be insufficient for recognizing generalized treatment for T1D before 2000. In 2000, the "Edmonton Protocol" was seen as a key advance in islet transplantation when all seven patients treated achieved and maintained insulin independence. 14 These patients subsequently received two or three different islet transplants, and the mean islet mass was 13 000 islet equivalents/kg in combination with a glucocorticoidfree immunosuppressive regimen with anti-interleukin-2 receptor antagonist antibody therapy. This success increased the interest and activity among countries involved in the CIT program. Subsequently, an international multicenter trial was conducted to explore the feasibility and reproducibility using the Edmonton Protocol. 15 This trial showed that the protocol could successfully restore long-term endogenous insulin secretion and glycemic stability in patients with T1D; however, insulin independence was not sustainable. The protocol showed that the long-term results were not enduring; hence, more advances were needed.
Hering et al 16 of hypoglycemia awareness, and protection from SHE in 87.5% of participants at 1-year follow up. 18 Improvement of health-related quality of life has also been reported. 19 The effectiveness of similar protocols, including thymoglobulin, tacrolimus, and MMF, has also been shown Determining whether islet transplantation can suppress the onset of diabetic complications is important. A prospective, crossover, cohort study indicated that islet transplantation is associated with lower progression of microvascular complications, including nephropathy, retinopathy, and polyneuropathy, compared with intensive medical therapy. 22 In addition, a health economic analysis showed that islet transplantation is cost-effective in the short term and cost-saving in the long term compared with standard insulin treatment. 23 Because the clinical significance of the islet transplant is accumulating, islet transplantation is approved and reimbursable by insurance companies or covered by national health systems in several countries, including Canada, Australia, and several European countries. 24 Table 1 summarizes the current and completed clinical trials and their results in islet transplantation. Figure 1 shows the possible factors that can lead to loss of pancreatic islets before, during, and after intraportal transplantation. Many improvements have been attempted to improve the loss of islet mass as a result of these factors.
TA B L E 1 Overview of selected clinical trials in islet transplantation

| REFINEMENTS IN IS LE T TR AN S PL ANTATI ON
| Islet isolation
Transplantation of a sufficient mass of viable islets is essential to achieve better graft survival. Although great progress has been made in the standardization of islet isolation, improvements are still needed. In brief, islet isolation methods are as follows. The procured and cold-preserved pancreas is distended with cold enzyme solution through the pancreatic duct in the cell processing unit. The distended pancreas is digested using the semiautomated method.
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The pancreatic digest is purified by continuous density gradient on a COBE 2991 cell processor (Terumo BCT, Gambro BCT, Inc., Lakewood, CO) under cold conditions. Liberated islets from grafts are cultured, and the islets are transplanted if the following releasing criteria are met: islet mass ≥5000 islet equivalents (IE)/kg (recipient body weight), islet purity ≥30%, membrane integrity-viability ≥70%, packed-tissue volume <10 mL, negative Gram stain, and content ≤5 endotoxin U/kg (recipient body weight). The islet isolation procedure seriously damages cellular and noncellular components of the Purification outcome after density gradient separation is highly variable as a result of inconsistencies in tissue densities.
Prior measurement of densities of islet and acinar tissue to customize the gradient range for actual purification likely maximizes islet recovery. A test gradient approach using multiple discontinuous gradients 33 and an analytical/continuous test gradient method, for predicting pancreatic tissue densities before largescale purification, 34 have been successfully introduced to minimize islet loss during purification.
| Islet engraftment
The isolated islets are transplanted from a catheter placed in the Approximately 25%-50% of the transplanted islets have been reported to maintain their functional reserve based on metabolic tests after transplantation. 36 Instant blood-mediated inflammatory reaction (IBMIR) is considered a main reason of substantial loss of islets during intraportal transplantation. 37 IBMIR is characterized by platelet activation, coagulation, and complement systems triggered when islets are exposed to ABO-compatible blood. 37 Further studies showed that tissue factor plays an important role in mediating IBMIR. 38 Several approaches demonstrated value in preventing IBMIR, including low molecular weight dextran sulfate, 39 islet surface heparinization, 40 and activated protein C. antagonist, anakinra, has also been applied in the clinical setting. 42 Combination of etanercept and anakinra led to the improvement in islet engraftment by the marginal-dose transplantation model. 43 Yasunami et al 44 46 Identification of pathways that regulate post-transplant detrimental inflammatory events seems to be a promising step toward improvement of islet transplantation outcome.
| Immunosuppression
As mentioned earlier, the Edmonton Protocol has shown the usefulness of steroid-free immunosuppressive therapy, 14, 15 and the usefulness of T cell-depleting antibody has been demonstrated in recent clinical outcomes. 17 Alemtuzumab (anti-CD52 antibody) is also used similarly to T cell-depleting antibody, apart from thymoglobulin, which adopted CIT-07. 18 The Edmonton group reported that the immunosuppressive method using alemtuzumab and etanercept induction combined with maintenance tacrolimus and MMF was well tolerated and showed higher 5-year insulin independence rates than the conventional Edmonton Protocol. 24 T cell-depleting antibody might suppress autoimmunity, and development of future research is expected.
Calcineurin inhibitor (tacrolimus) is mainly used in maintenance immunosuppressive therapy. In addition, sirolimus, an inhibitor of mTOR or MMF, is used in combination with calcineurin inhibitor.
Side-effects of calcineurin inhibitor, such as nephrotoxicity and impaired glucose tolerance, are of concern, but, currently, it shows the most effective maintenance immunosuppressive effect. Several at- 
| FUTURE PROS PEC TS
| Alternative transplant site
The liver might not be the "ideal site" for islet transplantation because early graft loss can occur by IBMIR, it is inaccessible for graft biopsy, and graft removal is impossible. Research should focus on alternative sites that ensure that islet transplantation remains a safer, well tolerated, and minimally invasive treatment, but that ensures improved islet graft survival.
Several clinical trials have been conducted or are ongoing to verify the safety and efficacy of an alternative transplant site. In a pilot study of autologous islet transplantation to test feasibility and safety of the bone marrow as a site for islet transplantation in humans, islets were successfully engrafted as shown by measurable C-peptide levels and histopathological evidence of insulin-producing cells in the biopsy of four patients who developed diabetes after total pancreatectomy. 48 This group started a clinical trial to evaluate safety and efficacy of the bone marrow as the site for pancreatic islet transplantation for T1D in humans (NCT01722682). In contrast, islets transplanted in the bone marrow seem to be less protected from the adaptive immune response in the presence of anti-CD3 treatment in a mouse model. 49 At the moment, the evidence is poor, and the expectation as an alternative transplant site is not very high, but future research is expected.
The omentum, which covers the abdominal organs, is highly vascularized, easily accessible, and drains into the portal system, is a part considered as an effective transplant site. Recent approach using an in situ-generated adherent, resorbable plasma-thrombin biological scaffold showed the potency of islets implanted onto the omentum by evaluation in diabetic rat and non-human primate (NHP) models. 50 Based on feasibility/efficacy data from this study, proposed by Luan and Iwata to achieve long-term allogeneic islet graft survival in prevascularized subcutaneous sites of diabetic rats without immunosuppression. Agarose rods with basic fibroblast growth factor and heparin were implanted in subcutaneous sites before transplantation. The islets were transplanted into the prevascularized sites after rod removal. Allogeneic islets transplanted into this site showed longterm graft survival and function in a diabetic rat model without immunosuppression. 53 This prevascularized method led to granulomatous tissue formation containing regulatory T cells that suppressed immune reactions for the grafts. 54 A similar approach was reported from the Edmonton group. They reported "device-less" islet transplantation into a prevascularized, subcutaneous site created by temporary placement of a vascular access catheter. 55 Other clinical reports of islet transplantation to intramuscular 56 or intraperitoneal 28 sites and other similar procedures have been made, and future development of an ideal transplantation site is desired.
| Alternative cell sources
Donor shortage is a major problem for patients who need islet transplantation. Realization of xenogeneic (porcine) islet transplantation and stem cell-derived β cells has been expected to overcome donor 60 and encapsulating devices. 61 Clinical trials have already been conducted in Oceania and South America for intraperitoneal porcine islet transplantation using microencapsulation. 28 The transmission of PERV has been a major safety concern; however, no transmission has been observed to date in human or NHP recipients. 57 Recent advances in genome-editing technology may become a major solution in the near future. 
| CON CLUS IONS
During the last 10 years, islet allotransplantation has developed into an established treatment modality for patients with T1D complicated by IAH and SHE. Further improvement of islet transplantation outcome is expected in the near future as a result of development of pancreatic islet isolation technique, improvement of islet engraftment method, and refinement of immunosuppressive therapy. In addition, with the development of alternative transplantation sites and new cell sources, including porcine islet cells and ES/iPS-derived β cells, "On-demand" and "Unlimited" cell therapy for diabetes will be established.
The minimally invasive nature of the procedure leads to the possibility of expanding the target disease in the future. For example, in the future, we can discuss strategies for implementing islet transplantation for children, as well as for conditions with severe β-cell failure other than T1D (ie, type 2 diabetes, cystic fibrosis, after pancreatectomy). To achieve target expansion, alternative transplant sites and alternative cell sources of pancreatic β cells are clearly a key to implementing this goal. 
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